Body Vision Medical Raises Growth Capital for Lung Imaging

Body Vision Medical develops LungVision, which provides AI-powered real-time image guidance for clinicians performing biopsy and localized treatment procedures for lung lesions. According to FinSMEs, the platform is intended to support early and definitive lung-cancer diagnosis and minimally invasive treatment.

Citybiz reports that the technology is used by thoracic surgeons and interventional pulmonologists during procedures involving difficult-to-reach lesions. BAC President and CEO Larry Kronick said in Citybiz that expanding national lung-cancer screening programs are creating opportunities for imaging and navigation technologies, and described Body Vision Medical's platform as designed to improve diagnostic yield during biopsy procedures.

FinSMEs reports that Body Vision Medical has access to 46 countries through more than 20 distributors. Citybiz reports that BAC brings healthcare business-development and international-market experience, while Sprim Global Investments is affiliated with an organization offering regulatory, clinical, and commercialization capabilities.

For ML and medical-imaging practitioners, the transaction is a reminder that clinical AI systems often depend on more than model performance. Comparable image-guidance deployments require integration with procedural workflows, imaging hardware, clinical validation, regulatory processes, and distributor networks before they can reach routine care settings.

The reported funding does not disclose the amount, valuation, product-performance metrics, regulatory clearances, or deployment counts. Those details would be necessary to assess the platform's commercial scale and clinical adoption more precisely.